Clinical trials recruiting for Metastatic Castration-resistant Prostate Cancer
67
Recruiting trials
39
US states with sites
40
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Enzalutamide | 11 |
| Docetaxel | 8 |
| Darolutamide | 7 |
| Abiraterone | 4 |
| Prednisone | 3 |
| Testosterone cypionate | 3 |
| ASP5541 | 2 |
| Abiraterone acetate | 2 |
| Bevacizumab | 2 |
| Cabazitaxel | 2 |
| Carboplatin | 2 |
| Cyclophosphamide | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 27 |
| Texas | 22 |
| Florida | 20 |
| New York | 20 |
| Ohio | 19 |
| Tennessee | 14 |
| South Carolina | 13 |
| Maryland | 12 |
| Virginia | 12 |
| Illinois | 10 |
| Wisconsin | 10 |
| Arizona | 9 |
Top cities
Houston, Texas 14Nashville, Tennessee 14New York, New York 14San Francisco, California 13Los Angeles, California 11Myrtle Beach, South Carolina 11San Antonio, Texas 9Baltimore, Maryland 8Boston, Massachusetts 8Charlottesville, Virginia 8
Self-screener
Recruiting trials
- 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
- 64Cu-GRIP B in Patients With Advanced Malignancies
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Phase I Trial of A-CAR032 in Participants With mCRPC
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
- A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
- A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
- A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
- A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
- ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
- Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
- Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
- Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
- EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
- Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
- Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Intestinal Akkermansia Muciniphila in Prostate Cancer
- Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
- PROCARE - PROstate Cancer Real World Evidence Registry
- PRostate Olaparib Real World Evidence Study
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
- Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
- Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
- Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
- Post Marketing Study on Pluvicto in Korea
- Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
- Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
- Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
- Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
- Study With [225Ac]Ac-FL-020 in mCRPC Participants
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
- Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
- The COSMYC Trial (COmbined Suppression of MYC)
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
- XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
- ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Related conditions
Trials recruiting for Metastatic Castration-resistant Prostate Cancer often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Metastatic Prostate Cancer 45Metastatic Hormone Sensitive Prostate Cancer 8mCRPC 8Prostatic Neoplasms, Castration-Resistant 13Prostatic Neoplasms 36Metastatic Castration-resistant Prostate Carcinoma 7mCRPC (Metastatic Castration-resistant Prostate Cancer) 12Endometrial cancer 68Colorectal cancer 1359
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Castration-resistant Prostate Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.